U.S. Exchange Worth Watching Stocks: Retrophin Inc (NASDAQ:RTRX), EXACT Sciences Corporation (NASDAQ:EXAS), Cooper Companies Inc (NYSE:COO) , Zogenix, Inc (NASDAQ:ZGNX)

Following U.S. Stocks were among the “Top Gainers” during Friday’s trade: Retrophin Inc (NASDAQ:RTRX), EXACT Sciences Corporation (NASDAQ:EXAS), Cooper Companies Inc (NYSE:COO) , Zogenix, Inc (NASDAQ:ZGNX)

Their insights are depicted underneath:

Retrophin Inc (NASDAQ:RTRX)’s shares picked up 9.32%, and closed at $15.37.

According to BUSINESS WIRE, Retrophin, Inc. (RTRX), stated fourth quarter and full year 2014 financial results.

Net product sales for the fourth quarter 2014 were $14.1 million
Net product sales for the full year 2014 were $28.2 million
Non-GAAP operating loss for the fourth quarter 2014 was $8.6 million, contrast to a non-GAAP operating loss of $8.9 million for the same period in 2013
Non-GAAP operating loss for the full year 2014 was $41.5 million, contrast to a non-GAAP operating loss of $17.3 million for the full year 2013
Cash, cash equivalents and marketable securities as of December 31, 2014 totaled $27.8 million.

Quarter Ended December 31, 2014:

Net product sales for the fourth quarter of 2014 were $14.1 million, contrast to no stated sales for the fourth quarter of 2013.

Selling, general and administrative expenses for the fourth quarter of 2014 were $18.7 million on a GAAP basis, contrast to $6.2 million for the same period in 2013. On an adjusted basis, selling, general and administrative expenses were $11.1 million for the fourth quarter of 2014, contrast to $3.4 million for the same period in 2013. The raise is largely attributable to the expansion of the Corporation’s business and support of commercial products, in addition to an extraordinary legal and financial expense of about $3.6 million largely related to the Corporation’s recent review of certain consulting and settlement contracts, the results of which were revealed in a regulatory filing on February 20, 2015.

Research and development expenses for the fourth quarter of 2014 were $14.9 million on a GAAP basis, contrast to $5.7 million for the same period in 2013. On an adjusted basis, research and development expenses were $12.4 million for the fourth quarter of 2014, contrast to $5.5 million for the same period in 2013. The raise reflects expenses related to the ongoing enrollment efforts for the Phase II DUET trial for sparsentan and pre-IND development of RE-024.

Net interest and other expense for the fourth quarter of 2014 was $10.3 million, contrast to $0.9 million for the same period in 2013. The change is primarily due to a $8.3 million raise in expense related to the Corporation’s derivative instruments and a $2.6 million raise in interest expense related to the Corporation’s senior convertible notes and term loan facility that was partially offset by a $1.5 million raise in realized gain on sales of marketable securities.

Net loss for the fourth quarter of 2014 was $29.0 million, or $1.10 per share on a GAAP basis, contrast to $12.8 million, or $0.70 per share for the same period in 2013. Adjusted net loss for the fourth quarter of 2014 was $9.4 million, or $0.36 per share, contrast to $8.5 million, or $0.46 per share for the same period in 2013.

Retrophin is a pharmaceutical corporation focused on the development, attainment and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are presently no viable options for patients.

EXACT Sciences Corporation (NASDAQ:EXAS) raised 9.23%, and closed at $24.50.

According to BUSINESS WIRE, Exact Sciences Corporation (EXAS), declared that Aetna, one of the country’s leading health plans, will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year contract will go into effect on April 1, 2015.

Cologuard is the first and only FDA approved noninvasive stool-based DNA (sDNA) screening test for colon cancer. The test will be accessible to Aetna’s Medicare Advantage members through their physician without a co-payment or co-insurance.

“We look forward to working with Aetna to provide their members with a new option for colon cancer screening. Colon cancer is most treatable when caught early, underscoring the importance of routine screening,” said Kevin Conroy, Chairman and CEO of Exact Sciences.

Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy to use screening test which they can do in the privacy of their own home. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation preceding to taking the test. It is the first noninvasive screening test for colorectal cancer that analyzes both sDNA and blood biomarkers to detect cancer and precancer. Cologuard is accessible by prescription only.

Exact Sciences Corp. (EXAS) is a molecular diagnostics corporation focused on the early detection and prevention of colorectal cancer. The corporation has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer.

Cooper Companies Inc (NYSE:COO) enhanced 9.08%, and closed at $180.26, hitting new 52-week high of $181.98.

According to GLOBE NEWSWIRE, The Cooper Companies Inc. (COO), declared financial results for the fiscal first quarter ended January 31, 2015.

Proceed raised 10% year-over-year to $445.2 million. CooperVision (CVI) proceed up 13% to $369.3 million. CooperSurgical (CSI) proceed down 4% to $75.8 million.
GAAP earnings per share (EPS) $1.25, down 22 cents or 15% from last year’s first quarter.
Non-GAAP EPS $1.75, up 17 cents or 11% from last year’s first quarter.

First Quarter GAAP Operating Highlights:

Proceed $445.2 million, up 10% from last year’s first quarter, up 5% pro forma (defined as constant currency and counting Sauflon proceed in both periods).
Gross margin 62% contrast with 65% in last year’s first quarter. Gross margin was negatively influenced primarily by currency and integration related expenses in part offset by favorable product mix. Not including integration related expenses, gross margin was 64% vs. 65% last year.
Operating margin 16% contrast with 20% in last year’s first quarter. The decrease was primarily due to integration related expenses and raised amortization arising from the Sauflon attainment. Not including these costs, operating margin would have been 23% vs. 22% last year.
Depreciation $29.3 million, up 23% from last year’s first quarter. Amortization $13.6 million, up 81% from last year’s first quarter primarily due to the Sauflon attainment.
Total debt raised $13.0 million from October 31, 2014, to $1,395.3 million, primarily due to the repurchase of shares.
Interest expense raised to $3.9 million contrast with $1.7 million in last year’s first quarter primarily due to higher debt associated with the attainment of Sauflon.
Cash offered by operations $79.8 million, capital expenditures $65.0 million, and not including attainment costs of $13.3 million resulted in free cash flow of $28.1 million.

The Cooper Companies, Inc. is a global medical device corporation publicly traded on the NYSE Euronext (COO). Cooper is dedicated to being A Quality of Life Corporation(TM) with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support.

Zogenix, Inc (NASDAQ:ZGNX), rose 8.05%, and closed at $1.88.

According to GLOBE NEWSWIRE, Zogenix, Inc. (ZGNX), a pharmaceutical corporation developing and commercializing products for the treatment of central nervous system (CNS) disorders, declared it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market closes on Tuesday, March 10, 2015, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to talk about these financial results and provide a corporation update.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be accessible starting March 10, 2015 at 7:30 p.m. ET (4:30 p.m. PT) until March 17, 2015, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International); passcode: 85134635. A replay of the webcast will also be accessible on the Investor Relations website for one month, through April 10, 2015.

Zogenix, Inc. (ZGNX) is a pharmaceutical corporation committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need innovative treatment alternatives to assist them return to normal daily functioning.